08:00 , Dec 20, 2012 |  BC Innovations  |  Strategy

MRC Technology extends reach

After six years of focusing on developing small molecule drug candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology , the commercialization arm of the country's Medical Research Council , is taking...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Company News

BioDiem, Serum Institute of India sales and marketing update

Serum Institute launched BioDiem's NasoVac live attenuated influenza vaccine (LAIV) against swine influenza A (H1N1) in India. Serum Institute has a sublicense to the vaccine under the World Health Organization's Pandemic Flu program. Nobilon International...
08:00 , Mar 8, 2010 |  BioCentury  |  Strategy

Merck's Chemical Test

Merck KGaA has put its own spin on the trend among mid-size European companies to choose between their prescription drugs and chemical businesses. Last week the company confirmed its commitment to a dual business strategy...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

Ligand, Merck deal

Ligand received a $1 million milestone payment from Merck's Organon N.V. subsidiary under a 2007 deal to discover, develop and commercialize compounds for indications including neuroscience and immunology. The payment was triggered by an undisclosed...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Company News

BioDiem, Merck sales and marketing update

BioDiem regained from Merck's Nobilon International B.V. unit full Japanese rights to market BioDiem's live attenuated influenza vaccine (LAIV) technology. The companies previously shared marketing rights to the technology in Japan under a 2004 deal....
08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Ligand, Merck deal

Ligand received a $2 million milestone payment from Merck's Organon N.V. subsidiary under a 2007 deal to discover, develop, and commercialize compounds for indications, including neuroscience and immunology. The milestone was triggered by an undisclosed...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

Saphris asenapine regulatory update

FDA approved an NDA from Schering-Plough for Saphris asenapine sublingual tablets for the acute treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Company News

Ligand, Schering-Plough deal

Ligand and Schering-Plough's Organon N.V subsidiary mutually ended a 2007 deal to discover, develop and commercialize compounds for indications including neuroscience and immunology. Organon is responsible for further development and commercialization of all compounds discovered...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

Saphris asenapine regulatory update

FDA's Psychopharmacologic Drugs Advisory committee voted 12-0 that Saphris asenapine from Schering-Plough was safe and effective for acute treatment of manic or mixed episodes in adults with bipolar I disorder. The committee voted 10-2 that...
07:00 , Jul 20, 2009 |  BC Week In Review  |  Clinical News

Remeron/Reflex mirtazapine regulatory update

Schering-Plough said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Remeron/Reflex mirtazapine to treat major depressive disorder in adults. Schering-Plough and Meiji Seika Kaisha Ltd. (Tokyo:2202, Tokyo, Japan), which has co-marketing rights to the...